NYSE · TAK
Healthcare · Drug Manufacturers - Specialty & Generic
$18.70
Up+$0.10 (+0.54%)
Updated Sep 16, 2026, 9:18 AM
SID Score
5.7/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
TAK closed at $18.70 after 20 trading sessions, up 3.60% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $18.74 | $18.765 | $18.61 | $18.70 | 2.68M |
| Sep 14, 2026 | $18.56 | $18.70 | $18.54 | $18.60 | 2.36M |
| Sep 11, 2026 | $18.38 | $18.445 | $18.20 | $18.26 | 2.15M |
| Sep 10, 2026 | $18.34 | $18.34 | $18.10 | $18.11 | 1.75M |
| Sep 9, 2026 | $18.18 | $18.35 | $18.1472 | $18.21 | 1.57M |
| Sep 8, 2026 | $18.53 | $18.65 | $18.28 | $18.32 | 3.14M |
| Sep 4, 2026 | $18.48 | $18.54 | $18.385 | $18.45 | 1.5M |
| Sep 3, 2026 | $18.75 | $18.835 | $18.52 | $18.71 | 2.85M |
| Sep 2, 2026 | $18.30 | $18.495 | $18.275 | $18.43 | 1.72M |
| Sep 1, 2026 | $18.18 | $18.405 | $18.18 | $18.23 | 1.9M |
| Aug 31, 2026 | $17.99 | $18.06 | $17.955 | $17.98 | 1.78M |
| Aug 28, 2026 | $18.00 | $18.11 | $17.96 | $18.03 | 1.81M |
| Aug 27, 2026 | $18.21 | $18.22 | $17.971 | $18.03 | 1.73M |
| Aug 26, 2026 | $18.32 | $18.38 | $18.2191 | $18.23 | 2.33M |
| Aug 25, 2026 | $18.21 | $18.355 | $18.21 | $18.35 | 1.25M |
| Aug 24, 2026 | $18.24 | $18.26 | $18.11 | $18.24 | 2.23M |
| Aug 21, 2026 | $18.09 | $18.245 | $18.08 | $18.18 | 1.48M |
| Aug 20, 2026 | $18.25 | $18.34 | $18.105 | $18.13 | 2.23M |
| Aug 19, 2026 | $18.22 | $18.495 | $18.22 | $18.34 | 3.31M |
| Aug 18, 2026 | $17.86 | $18.16 | $17.8341 | $18.05 | 3.81M |
The latest Smart Investors Daily articles mentioning TAK.
TAK research
Company profile and research snapshot.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 11, 2020 | JP Morgan | Overweight | — |
| Nov 1, 2019 | Cowen & Co. | Market Perform | — |
| Sep 24, 2019 | Jefferies | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 10, 2026
Plump joined Takeda during a turbulent period, pushed the company to work more closely with young biotechs and will leave it with what CEO Julie Kim called a “lasting foundation.”
Yahoo · Sep 9, 2026
MALMO, Sweden & WILMINGTON, Del., September 09, 2026--Trialbee, the global patient recruitment leader reimagining clinical trials with AI, will present alongside Takeda at DPHARM 2026 taking place September 15–16 in Boston.
Yahoo · Sep 9, 2026
OSAKA, Japan & CAMBRIDGE, Mass., September 09, 2026--Takeda (TSE:4502/NYSE:TAK) announced that the New England Journal of Medicine published results from two Phase 3 studies evaluating oveporexton (ORZEYFUL), an oral orexin receptor 2 (OX2R) agonist, in people with narcolepsy type 1 (NT1).1 Oveporexton is the first and only medicine to treat the underlying cause of NT1.
Yahoo · Sep 9, 2026
LOUISVILLE, Ky., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected by Takeda Pharmaceuticals as an ultra-narrow limited distribution partner for MIMRYLO™ (rusfertide), which is indicated for the treatment of erythrocytosis in adults with polycythemia vera (PV).1 “We are proud to expand our partnership with Takeda and support the launch of MIMRYLO, a first-of-its kind rare blood cancer treatment for adults living with polycythemia
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TAK.
